Antifibrotic Agents | List of Frontiers open access articles

Mini Review

Accepted on 24 Feb 2026

Pathogenesis and Immune Regulation of Rheumatoid Arthritis-Associated Interstitial Lung Disease: From Basic Research to Clinical Implications

in Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders

Yaxin Cheng
Yu Shan
Yixin Zheng
Fuyu Zhao
Yiming Shi
Chenyang Song
Yunshen Li
Jianan Zhao
Cen Chang
YuGuang Wang

Frontiers in Immunology

Review

Published on 07 Apr 2020

New Therapeutic Targets in Autoimmune Cholangiopathies

in Gastroenterology

Alessio Gerussi
Martina Lucà
Laura Cristoferi
Vincenzo Ronca
Clara Mancuso
Chiara Milani
Daphne D'Amato
Sarah Elizabeth O'Donnell
Marco Carbone
Pietro Invernizzi

Frontiers in Medicine

doi 10.3389/fmed.2020.00117

12,563 views
28 citations

Original Research

Published on 17 Jul 2020

Functional Gene Module–Based Identification of Phillyrin as an Anticardiac Fibrosis Agent

in Cardiovascular and Smooth Muscle Pharmacology

Lei Wang
Wuxia Zhang
Ziwen Lu
Baofu Wang
Yang Li
Jingjing Yang
Peng Li
Mingjing Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2020.01077

4,680 views
13 citations

Review

Published on 31 May 2017

Novel Anti-fibrotic Therapies

in Cardiovascular and Smooth Muscle Pharmacology

Benita L. McVicker
Robert G. Bennett

Frontiers in Pharmacology

doi 10.3389/fphar.2017.00318

20,441 views
68 citations

Original Research

Published on 01 Sep 2023

Endotrophin as a risk marker of mortality and kidney complications in a type 1 diabetes cohort

in Molecular Diagnostics and Therapeutics

Alexandra Louise Møller
Ninna Hahn Tougaard
Daniel Guldager Kring Rasmussen
Federica Genovese
Pernille Falberg Rønn
Tine Willum Hansen
Morten Asser Karsdal
Peter Rossing

Frontiers in Molecular Biosciences

doi 10.3389/fmolb.2023.1229579

3,940 views
2 citations

Original Research

Published on 17 Dec 2018

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

in Respiratory Pharmacology

Shaney L. Barratt
Sarah Mulholland
Khaled Al Jbour
Henry Steer
Markus Gutsche
Noeleen Foley
Rajiv Srivastava
Charles Sharp
Huzaifa I. Adamali

Frontiers in Pharmacology

doi 10.3389/fphar.2018.01480

8,107 views
42 citations

Original Research

Published on 05 Jun 2025

Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland

in Respiratory Pharmacology

Sebastian Majewski
Katarzyna Górska
Katarzyna B. Lewandowska
Magdalena M. Martusewicz-Boros
Małgorzata Sobiecka
Wojciech J. Piotrowski

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1586197

3,768 views
1 citation

Articles

Pathogenesis and Immune Regulation of Rheumatoid Arthritis-Associated Interstitial Lung Disease: From Basic Research to Clinical Implications

New Therapeutic Targets in Autoimmune Cholangiopathies

Functional Gene Module–Based Identification of Phillyrin as an Anticardiac Fibrosis Agent

Novel Anti-fibrotic Therapies

Endotrophin as a risk marker of mortality and kidney complications in a type 1 diabetes cohort

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland